|Número de publicación||US6615081 B1|
|Tipo de publicación||Concesión|
|Número de solicitud||US 09/837,660|
|Fecha de publicación||2 Sep 2003|
|Fecha de presentación||19 Abr 2001|
|Fecha de prioridad||26 Oct 1998|
|Número de publicación||09837660, 837660, US 6615081 B1, US 6615081B1, US-B1-6615081, US6615081 B1, US6615081B1|
|Inventores||Birinder R. Boveja|
|Cesionario original||Birinder R. Boveja|
|Exportar cita||BiBTeX, EndNote, RefMan|
|Citas de patentes (14), Citada por (161), Clasificaciones (11), Eventos legales (4)|
|Enlaces externos: USPTO, Cesión de USPTO, Espacenet|
This is a Continuation-in-Part application of Ser. No. 09/727,570 filed Nov. 30, 2000, now U.S. Pat. No. 6,356,788, which is a Continuation-in-Part of Ser. No. 09/178,060 filed Oct. 26, 1998, now U.S. Pat. No. 6,205,359. Priority is claimed from these applications, and the prior applications being incorporated herein by reference. Further, this application is related to the following applications filed Apr. 17, 2001, entitled,
a) Apparatus and method for electrical stimulation adjunct (add-on) therapy of atrial fibrillation, inappropriate sinus tachycardia, and refractory hypertension with and external stimulator.
b) Apparatus and method for adjunct (add-on) treatment of coma and traumatic brain injury with neuromodulation using an external stimulator.
c) Apparatus and method for neuromodulation therapy for obesity and compulsive eating disorders using an implantable lead-receiver and an external stimulator.
This invention relates generally to medical device therapy for diabetes, more specifically to a medical device system for adjunct therapy of diabetes by neuromodulation of a selected nerve or nerve bundle utilizing an implanted lead-receiver and an external stimulator.
Diabetes is a significant health problem affecting millions of Americans. It is the leading risk factor in coronary heart disease and stroke, leading cause of blindness, end-stage renal disease, and a major contributor to lower extremity amputations. Diabetes mellitus is a heterogeneous group of diseases, all of which ultimately lead to hyperglycemia (an elevation of glucose in the blood) and excretion of glucose in the urine as hyperglycemia increases. Diabetes mellitus is also characterized by the inability to reabsorb water, which results in increased urine production (polyuria), excessive thirst (polydipsia), and excessive eating (polyphagia).
The regulation of glucose levels in the body is by the hormone insulin. Insulin is produced by the beta cells of the pancreas from the tissue called islets of Langerhans (shown schematically in FIG. 1). The pancreas is a flattened organ located just below the stomach. Insulin lowers blood sugar concentration by facilitating the movement of glucose into body tissues. Insulin is intimately involved in the regulation not only of glucose metabolism but also of protein and fat metabolism. Therefore, it is not suprising that all of the major foodstuffs play some role in regulating insulin release. Even though blood glucose level is the most important determinant that increases insulin secretion, other factors and conditions also influence insulin release. Among the other factors, and most notably for this invention is the condition that parasympathetic stimulation also increases insulin secretion.
Nerves have trophic influences on tissues, and the secretion of insulin is stimulated by vagal nerve fibers. Decreased glucose tolerance following vagotomy (interruption of the imulses carried by the vagus nerve) has been reported in human subjects, and sympathetic stimulation via the splanchnic nerve inhibits insulin release. The central nervous system also plays a role in regulating insulin secretion, and the outflow probably occurs via the hypothalamus and the autonomic nervous system.
In this invention diabetes is treated by electrical stimulation neuromodulation of the vagal nerve fibers with an implanted lead-receiver and an external stimulator with predetermined programs. The neuromodulation thus increasing the secretion of insulin by the pancreas, for adjunct (add-on) treatment of diabetes.
Observations on the profound effect of electrical stimulation of the vagus nerve on central nervous system (CNS) activity extends back to the 1930's. The vagus nerve 54 provides an easily accessible, peripheral route to modulate central nervous system (CNS) function. Other cranial nerves can be used for the same purpose, but the vagus nerve 54 is preferred because of its easy accessibility. In the human body there are two vagus nerves (VN), the right VN and the left VN. Each vagus nerve is encased in the carotid sheath along with the carotid artery and jugular vein. The innervation of the right and left vagus nerves is different. The innervation of the right vagus nerve is such that stimulating it results in profound bradycardia (slowing of the heart rate). The left vagus nerve has some innervation to the heart, but mostly innervates the visceral organs such as the gastrointestinal tract. It is known that stimulation of the left vagus nerve does not cause any significant deleterious side effects.
One of the fundamental features of the nervous system is its ability to generate and conduct electrical impulses. These can take the form of action potentials, which is defined as a single electrical impulse passing down an axon, and is shown schematically in FIG. 2. The top portion of the figure shows conduction over mylinated axon (fiber) and the bottom portion shows conduction over nonmylinated axon (fiber). These electrical signals will travel along the nerve fibers.
The nerve impulse (or action potential) is an “all or nothing” phenomenon. That is to say, once the threshold stimulus intensity is reached an action potential 7 will be generated. This is shown schematically in FIG. 3. The bottom portion of the figure shows a train of action potentials.
Most nerves in the human body are composed of thousands of fibers of different sizes. This is shown schematically in FIG. 4. The different sizes of nerve fibers, which carry signals to and from the brain, are designated by groups A, B, and C. The vagus nerve, for example, may have approximately 100,000 fibers of the three different types, each carrying signals. Each axon or fiber of that nerve conducts only in one direction, in normal circumstances.
In a cross section of peripheral nerve it is seen that the diameter of individual fibers vary substantially. The largest nerve fibers are approximately 20 μm in diameter and are heavily myelinated (i.e., have a myelin sheath, constituting a substance largely composed of fat), whereas the smallest nerve fibers are less than 1 μm in diameter and are unmyelinated. As shown in FIG. 5, when the distal part of a nerve is electrically stimulated, a compound action potential is recorded by an electrode located more proximally. A compound action potential contains several peaks or waves of activity that represent the summated response of multiple fibers having similar conduction velocities. The waves in a compound action potential represent different types of nerve fibers that are classified into corresponding functional categories as shown in the table below,
The diameters of group A and group B fibers include the thickness of the myelin sheaths. Group A is further subdivided into alpha, beta, gamma, and delta fibers in decreasing order of size. There is some overlapping of the diameters of the A, B, and C groups because physiological properties, especially in the form of the action potential, are taken into consideration when defining the groups. The smallest fibers (group C) are unmyelinated and have the slowest conduction rate, whereas the myelinated fibers of group B and group A exhibit rates of conduction that progressively increase with diameter.
Compared to unmyelinated fibers, myelinated fibers are typically larger, conduct faster, have very low stimulation thresholds, and exhibit a particular strength-duration curve or respond to a specific pulse width versus amplitude for stimulation. The A and B fibers can be stimulated with relatively narrow pulse widths, from 50 to 200 microseconds (μs), for example. The A fiber conducts slightly faster than the B fiber and has a slightly lower threshold. The C fibers are very small, conduct electrical signals very slowly, and have high stimulation thresholds typically requiring a wider pulse width (300-1,000 μs) and a higher amplitude for activation. Because of their very slow conduction, C fibers would not be highly responsive to rapid stimulation. Selective stimulation of only A and B fibers is readily accomplished. The requirement of a larger and wider pulse to stimulate the C fibers, however, makes selective stimulation of only C fibers, to the exclusion of the A and B fibers, virtually unachievable inasmuch as the large signal will tend to activate the A and B fibers to some extent as well.
The vagus nerve is composed of somatic and visceral afferents and efferents. Usually, nerve stimulation activates signals in both directions (bi-directionally). It is possible however, through the use of special electrodes and waveforms, to selectively stimulate a nerve in one direction only (unidirectionally). The vast majority of vagus nerve fibers are C fibers, and a majority are visceral afferents having cell bodies lying in masses or ganglia in the skull. The central projections terminate largely in the nucleus of the solitary tract, which sends fibers to various regions of the brain (e.g., the thalamus, hypothalamus and amygdala).
Vagus nerve stimulation is a means of directly affecting central function. As shown in FIG. 6, cranial nerves have both afferent pathway 19 (inward conducting nerve fibers which convey impulses toward the brain) and efferent pathway 21 (outward conducting nerve fibers which convey impulses to an effector). The vagus nerve 54 is composed of 80% afferent sensory fibers carrying information to the brain from the head, neck, thorax, and abdomen. The sensory afferent cell bodies of the vagus reside in the nodose ganglion and relay information to the nucleus tractus solitarius (NTS).
FIG. 7 shows the nerve fibers traveling through the spinothalamic tract to the brain. The afferent fibers project primarily to the nucleus of the solitary tract (shown schematically in FIG. 8) which extends throughout the length of the medulla oblangata. A small number of fibers pass directly to the spinal trigeminal nucleus and the reticular formation. As shown in FIG. 8, the nucleus of the solitary tract has widespread projection to cerebral cortex, basal forebrain, thalamus, hypothalamus, amygdala, hippocampus, dorsal raphe, and cerebellum. In summary neuromodulation of the vagal nerve fibers increase the secretion of insulin by the pancreas, because of the connections of the nucleus tractus solitarus to the appropriate centers in the brain.
One type of non-pharmacologic therapy for diabetes is generally directed to the use of an implantable lead and an implantable pulse generator technology or “cardiac pacemaker-like” technology, i.e. stimulation with an implantable Neurocybernetic Prosthesis. In the prior art, the pulse generator is programmed via a “personnel computer (PC)” based programmer that is adapted with a programmer wand, which is placed on top of the skin over the pulse generator implant site. This is shown in FIG. 9. Also, in the prior art each parameter is programmed independent of the other parameters. Therefore, millions of different combinations of programs are possible. In the current patent application, limited number of programs, say less than 20, are built-in. Some of the other prior art is summarized below.
U.S. Pat. No. 3,796,221 (Hagfors) is directed to controlling the amplitude, duration and frequency of electrical stimulation applied from an externally located transmitter to an implanted receiver by inductively coupling. Electrical circuitry is schematically illustrated for compensating for the variability in the amplitude of the electrical signal available to the receiver because of the shifting of the relative positions of the transmitter-receiver pair. By highlighting the difficulty of delivering consistent pulses, this patent points away from applications such as the current application, where consistent therapy needs to be continuously sustained over a prolonged period of time. The methodology disclosed is focused on circuitry within the receiver, which would not be sufficient when the transmitting coil and receiving coil assume significantly different orientation, which is likely in the current application. The present invention discloses a novel approach for solving this problem.
U.S. Pat. Nos. 4,702,254, 4,867,164 and 5,025,807 (Zabara) generally disclose animal research and experimentation related to epilepsy and the like and are directed to stimulating the vagas nerve by using “pacemaker-like” technology, such as an implantable pulse generator. The pacemaker technology concept consists of a stimulating lead connected to a pulse generator (containing the circuity and DC power source) implanted subcutaneously or submuscularly, somewhere in the pectoral or axillary region, and programming with an external personal computer (PC) based programmer. Once the pulse generator is programmed for the patient, the fully functional circuitry and power source are fully implanted within the patient's body. In such a system, when the battery is depleted, a surgical procedure is required to disconnect and replace the entire pulse generator (circuitry and power source). These patents neither anticipate practical problems of an inductively coupled system, nor suggest solutions to the same for an inductively coupled system for neuromodulation therapy.
U.S. Pat. No. 5,231,988 (Wernicke et al) is generally directed to treatment of endocrine disorders by nerve stimulation with an implantable neurocybernetic prosthesis (NCP).
U.S. Pat. No. 5,304,206 (Baker, Jr. et al) is directed to activation techniques for implanted medical stimulators. The system uses either a magnet to activate the reed switch in the device, or tapping which acts through the piezoelectric sensor mounted on the case of the implanted device, or a combination of magnet use and tapping sequence.
U.S. Pat. No. 4,573,481 (Bullara) is directed to an implantable helical electrode assembly configured to fit around a nerve. The individual flexible ribbon electrodes are each partially embedded in a portion of the peripheral surface of a helically formed dielectric support matrix.
U.S. Pat. No. 3,760,812 (Timm et al.) discloses nerve stimulation electrodes that include a pair of parallel spaced apart helically wound conductors maintained in this configuration.
U.S. Pat. No. 4,979,511 (Terry) discloses a flexible, helical electrode structure with an improved connector for attaching the lead wires to the nerve bundle to minimize damage.
Apparatus and method for neuromodulation, in the current application has several advantages over the prior art implantable pulse generator. The external stimulator described here can be manufactured at a fraction of the cost of an implantable pulse generator. The therapy can be freely applied without consideration of battery depletion. Surgical replacement of pulse generator is avoided. The programming is much simpler, and can be adjusted by the patient within certain limits for patient comfort. And, the implanted hardware is much smaller.
The system and method of the current invention also overcomes many of the disadvantages of the prior art by simplifying the implant and taking the programmability into the external stimulator. Further, the programmability of the external stimulator can be controlled remotely, via the wireless medium, as described in a co-pending application. The system and method of this invention uses the patient as his/her own feedback loop. Once the therapy is prescribed by the physician, the patient can receive the therapy as needed based on symptoms, and the patient can adjust the stimulation within prescribed limits for his/her own comfort.
The present invention is directed to system and methods for adjunct (add-on) electrical neuromodulation therapy for diabetes and blood glucose regulation, using predetermined programs with an external stimulator. The system consists of an implantable lead-receiver containing passive circuitry, electrodes, and a coil for coupling to the external stimulator. The external stimulator, which may be worn on a belt or carried in a pocket contains, electronic circuitry, power source, primary coil, and predetermined programs. The external primary coil and subcutaneous secondary coil are inductively coupled. The patient may selectively activate stimulation corresponding to meals, or leave the stimulation on according to predetermined program.
In one aspect of the invention the pulse generator contains a limited number of predetermined programs packaged into the stimulator, which can be accessed directly without a programmer. The limited number of programs can be any number of programs even as many as 100 programs, and such a number is considered within the scope of this invention.
In another feature of the invention, the system provides for proximity sensing means between the primary (external) and secondary (implanted) coils. Utilizing current technology, the physical size of the implantable lead-receiver has become relatively small. However, it is essential that the primary (external) and secondary (implanted) coils be positioned appropriately with respect to each other. The sensor technology incorporated in the present invention aids in the optimal placement of the external coil relative to a previously implanted subcutaneous coil. This is accomplished through a combination of external and implantable components.
In another feature of the invention, the external stimulator has predetermined fixed programs, as well as a manual “on” and “off” button. Each of these programs has a unique combination of pulse amplitude, pulse width, frequency of stimulation, on-time and off-time. After the therapy has been initiated by the physician, the patient has a certain amount of flexibility in adjusting the intensity of the therapy (level of stimulation). The patient has the flexibility to decrease (or increase) the level of stimulation (within limits). The manual “on” button gives the patient flexibility to immediately start the stimulation pattern at any time. Of the pre-determined programs, patients do not have access to at least one of the programs, which can be activated only by the physician, or an appropriate medical person.
Various other features, objects and advantages of the invention will be made apparent from the following description taken together with the drawings.
For the purpose of illustrating the invention, there are shown in accompanying drawing forms which are presently preferred, it being understood that the invention is not intended to be limited to the precise arrangement and instrumentalities shown.
FIG. 1 is a schematic diagram of pancreatic tissue.
FIG. 2 is a schematic diagram of myelinated and nonmyelinated axon.
FIG. 3 is a schematic diagram of a single nerve impulse and a train of nerve impulses.
FIG. 4 is a diagram of the structure of a peripheral nerve.
FIG. 5 is a diagram showing recordings of compound action potentials.
FIG. 6 is a schematic diagram of brain showing afferent and efferent pathways.
FIG. 7 is a schematic diagram showing pathways along the spinothalamic tract.
FIG. 8 is a schematic diagram showing relationship of Nucleus of the Solitary Track and how it relays information to other parts of the brain.
FIG. 9 is a prior art figure showing an implantable neurocybernetic prosthesis, and a personnel computer based programmer along with an external sensor.
FIG. 10 is a schematic diagram of a patient with an implanted read receiver and an external stimulator with predetermined programs.
FIG. 11A is a diagram showing the implanted lead-receiver in contact with the vagus nerve at the distal end.
FIG. 11B is a diagram showing two coils along their axis in a configuration such that the mutual inductance would be maximum.
FIG. 12 shows external stimulator coupled to the implanted unit.
FIG. 13 is a top-level block diagram of the external stimulator and proximity sensing mechanism.
FIG. 14 is a diagram showing the proximity sensor circuitry.
FIG. 15 is a block diagram of programmable array logic interfaced to the programming station.
FIG. 16 is a block diagram showing details of programmable logic array unit.
FIG. 17 is a diagram showing details of the interface between the programmable array logic and interface unit.
FIG. 18 is a diagram showing the circuitry of the pulse generator.
FIG. 19 shows the pulse train to be transmitted to the implant unit.
FIG. 20 shows the ramp-up and ramp-down characteristic of the pulse train.
FIG. 21 is an overall schematic diagram of the external stimulator, showing wireless communication.
FIG. 22 is a schematic diagram showing application of Wireless Application Protocol (WAP).
FIG. 23A is a diagram of the implanted lead receiver.
FIG. 23B is a schematic diagram of the proximal end of the lead receiver implanted lead receiver.
FIG. 24 is a schematic of the passive circuitry in the implanted lead-receiver.
FIG. 25A is a schematic of an alternative embodiment of the implanted lead-receiver.
FIG. 25B is another alternative embodiment of the implanted lead-receiver.
FIG. 26 is a diagram of a hydrogel electrode.
FIG. 27 is a diagram of a lead-receiver utilizing a fiber electrode at the distal end.
FIG. 28 is a diagram of a fiber electrode wrapped around Dacron polyester.
FIG. 29 is a diagram of a lead-receiver with a spiral electrode.
FIG. 30 is a diagram of an electrode embedded in tissue.
FIG. 31 is a diagram of an electrode containing steroid drug inside.
FIG. 32 is a diagram of an electrode containing steroid drug in a silicone collar at the base of electrode.
FIG. 33 is a diagram of an electrode with steroid drug coated on the surface of the electrode.
FIG. 34 is a diagram of cross sections of implantable lead-receiver body showing different lumens.
The following description is of the current embodiment for carrying out the invention. This description is not to be taken in a limiting sense, but is made merely for the purpose of describing the general principles of the invention. The scope of the invention should be determined with reference to the claims.
The system and method of neuromodulation therapy of this invention consists of delivering pulsed electrical stimulation, using an implanted lead-receiver and an external stimulator with predetermined programs of stimulation. The implanted lead-receiver and external stimulator are inductively coupled. The predetermined programs contain unique combination of stimulation parameters for neuromodulation, and differ in the aggressiveness of the therapy. Some of the predetermined programs are “locked-out” to the patient or caretaker, and can be accessed and controlled by the physician only.
Referring now to FIG. 10, which shows a schematic diagram of a patient 32 with an implantable lead-receiver 34 and an external stimulator 42, clipped on to a belt 44 in this case. The external stimulator 42, may alternatively be placed in a pocket or other carrying device. The primary (external) coil 46 of the external stimulator 42 is inductively coupled to the secondary (implanted) coil 48 of the implanted lead-receiver 34. As shown in FIG. 11A, the implantable lead-receiver 34 has circuitry at the proximal end 49, and has two stimulating electrodes at the distal end 61,62. The negative electrode (cathode) 61 is positioned towards the brain and the positive electrode (anode) 62 is positioned away from the brain. During the surgical implant procedure, the stimulating electrodes are tunneled subcutaneously and the spiral shaped electrodes are wrapped around the vagus nerve 54 which is surgically isolated from the carotid artery 56 and jugular vein 58. The incisions are surgically closed and the chronic stimulation process can begin when the tissues are healed from the surgery.
For therapy to commence, the primary (external) coil 46 is placed on the skin on top of the surgically implanted (secondary) coil 48. An adhesive tape is then placed on the skin 60 and external coil 46 such that the external coil 46, is taped firmly to the skin 60. For efficient energy transfer to occur, it is important that the primary (external) and secondary (internal) coils 46,48 be positioned along the same axis and be optimally positioned relative to each other (FIG. 11B). In the present embodiment, the external coil 46 is connected to proximity sensing circuitry 50. The correct positioning of the external coil 46 with respect to the internal coil 48 is indicated by turning “on” of a light emitting diode (LED) on the external stimulator 42.
Optimal placement of the external (primary) coil 46 is done with the aid of proximity sensing circuitry incorporated in the system. Proximity sensing occurs utilizing a combination of external and implantable or internal components. The internal components contains a relatively small magnet composed of materials that exhibit Giant Magneto-Resistor (GMR) characteristics such as Samarium-cobalt, a coil, and passive circuitry. As shown in FIG. 12, the external coil 46 and proximity sensor circuitry 50 are rigidly connected in a convenient enclosure which is attached externally on the skin. The sensors measure the direction of the field applied from the magnet to sensors within a specific range of field strength magnitude. The dual sensors exhibit accurate sensing under relatively large separation between the sensor and the target magnet. As the external coil 46 placement is “fine tuned”, the condition where the external (primary) coil 46 comes in optimal position, i.e. is located adjacent and parallel to the subcutaneous (secondary) coil 48, along its axis, is recorded and indicated by a light emitting diode (LED) on the external stimulator 42.
FIG. 13 shows an overall block diagram of the components of the external stimulator and the proximity sensing mechanism. The proximity sensing components are the primary (external) coil 46, supercutaneous (external) proximity sensors 198, 202 (FIG. 14) in the proximity sensor circuit unit 50, and a subcutaneous secondary coil 48 with a Giant Magneto Resister (GMR) magnet 53 associated with the proximity sensor unit. The proximity sensor circuit 50 provides a measure of the position of the secondary implanted coil 48. The signal output from proximity sensor circuit 50 is derived from the relative location of the primary and secondary coils 46, 48. The coil sub-assemblies consist of the coil and the associated electronic components, that are rigidly connected to the coil.
The proximity sensors (external) contained in the proximity sensor circuit 50 detect the presence of a GMR magnet 53, composed of Samarium Cobalt, that is rigidly attached to the subcutaneous secondary coil 48. The proximity sensors, are mounted externally as a rigid assembly and sense the actual separation between the coils, also known as the proximity distance. In the event that the distance exceeds the system limit, the signal drops off and an alarm sounds to indicate failure of the production of adequate signal in the secondary implanted circuit 167, as applied in the present embodiment of the device. This signal is provided to the location indicator LED 140.
FIG. 14 shows the circuit used to drive the proximity sensors 198, 202 of the proximity sensor circuit. The two proximity sensors 198, 202 obtain a proximity signal based on their position with respect to the implanted GMR magnet 53. This circuit also provides temperature compensation. The sensors 198, 202 are ‘Giant Magneto Resistor’ (GMR) type sensors packaged as proximity sensor unit 50. There are two components of the complete proximity sensor circuit 51. One component is mounted supercutaneously 50, and the other component, the proximity sensor signal control unit 57 is within the external stimulator 42. The resistance effect depends on the combination of the soft magnetic layer of magnet 53, where the change of direction of magnetization from external source can be large, and the hard magnetic layer, where the direction of magnetization remains unchanged. The resistance of this sensor varies along a straight motion through the curvature of the magnetic field. A bridge differential voltage is suitably amplified and used as the proximity signal.
The Siemens GMR B6 (Siemens Corp., Special Components Inc. New Jersey) is used for this function in the present embodiment. The maximum value of the peak-to-peak signal is observed as the external magnetic field becomes strong enough, at which point the resistance increases, resulting in the increase of the field-angle between the soft magnetic and hard magnetic material. The bridge voltage also increases. In this application, the two sensors 198, 202 are oriented orthogonal to each other.
The distance between the magnet and sensor is not relevant as long as the magnetic field is between 5 and 15 KA/m, and provides a range of distances between the sensors 198, 202 and the magnetic material 53. The GMR sensor registers the direction of the external magnetic field. A typical magnet to induce permanent magnetic field is approximately 15 by 8 by 5 mm3, for this application and these components. However, the sensors 198, 202 are sensitive to temperature, such that the corresponding resistance drops as temperature increases. This effect is quite minimal until about 1000° C. A full bridge circuit is used for temperature compensation, as shown in temperature compensation circuit 50 of FIG. 14. The sensors 198, 202 and a pair of resistors 200, 204 are shown as part of the bridge network for temperature compensation. It is also possible to use a full bridge network of two additional sensors in place of the resistors 200, 204.
The signal from either proximity sensor 198, 202 is rectangular if the surface of the magnetic material is normal to the sensor and is radial to the axis of a circular GMR device. This indicates a shearing motion between the sensor and the magnetic device. When the sensor is parallel to the vertical axis of this device, there is a fall off of the relatively constant signal at about 25 mm. separation. The GMR sensor combination varies its resistance according to the direction of the external magnetic field, thereby providing an absolute angle sensor. The position of the GMR magnet can be registered at any angle from 0 to 360 degrees.
The external stimulator shown in FIG. 13, with indicator unit 140 which is provided to indicate proximity distance or coil proximity failure (for situations where the patch containing the external coil 46, has been removed, or is twisted abnormally etc.). Indication is also provided to assist in the placement of the patch. In case of general failure, a red light with audible signal is provided when the signal is not reaching the subcutaneous circuit. The indicator unit 140 also displays low battery status. The information on the low battery, normal and out of power conditions will forewarn the user of the requirements of any corrective actions.
As was shown in FIG. 13, the programmable parameters are stored in a programmable logic 304. The predetermined programs stored in the external stimulator are capable of being modified through the use of a separate Programming Station 77. FIG. 15 shows the Programmable Array Logic Unit 304 and interface unit 312 interfaced to the programming station 77. The programming station 77 can be used to load new programs, change the predetermined programs, or the program parameters for various stimulation programs. The programming station is connected to the Programmable Array Unit 75, shown in FIG. 16 (comprising programmable array logic 304 and interface unit 312) with an RS232-C serial connection. The main purpose of the serial line interface is to provide an RS232-C standard interface. This method enables any portable computer with a serial interface to communicate and program the parameters for storing the various programs. The serial communication interface receives the serial data, buffers this data and converts it to a 16 bit parallel data. The Programmable Array Logic 304 component of Programmable Array Unit 75 receives the parallel data bus and stores or modifies the data into a random access matrix 340 (FIG. 16). This array of data also contains special logic and instructions along with the actual data. These special instructions also provide an algorithm for storing, updating and retrieving the parameters from long-term memory. The Programmable logic Array Unit 304, interfaces with Long Term Memory to store the predetermined programs 71. All the previously modified programs can be stored here for access at any time, as well as, additional programs can be locked out for the patient. The programs consist of specific parameters and each unique program will be stored sequentially in long-term memory. A battery unit 310 is present to provide power to all the components shown above. The logic for the storage and decoding is stored in the Random Addressable Storage Matrix (RASM) 340 (FIG. 16).
FIG. 16 shows greater details for the Programmable Logic Array Unit 304. The Input Buffer block 343 is where the serial data is stored in temporary register storage. This accumulation allows for the serial to parallel conversion to occur. The serial to 16 bit parallel block 346 sets up 16 bits of data, as created from the RS232-C serial data. This parallel data bus will communicate the data and the address information. The decoder block 344 decodes address information for the Random Addressable Logic Storage Matrix 340 from which to access the data i.e. programmer parameters. The Output Buffer 342 provides an interface to the Long Term Memory 71.
FIG. 17 shows schematically the details of the interface between the Programmable Array Logic 304 and Interface Unit 312 which is connected to the Predetermined Programs block (Long Term Memory) 71. The patient override 73 is essentially a control scheme for initializing or starting a program at any intermediate point. The Programmable array provides a reconfigurable mechanism to store data and associated instructions for the programs. It supports adding, modifying or retrieving the data from a Random Addressable Logic Storage Matrix 340. This is also a widely accepted scheme for treating “flexible” logic description and control. It is flexible by providing the ability to reprogram and even redesign existing programs previously installed as predetermined programs. It allows the manufacturer or authorized user to create, and modify the programs for execution.
The pulse generator circuitry, shown schematically in FIG. 18, exhibits typical multivibrator functionality. This circuit produces regularly occurring pulses where the amplitude, pulse width and frequency is adjustable. The battery 310 is the main external power source for this circuit. The capacitor 450 is connected in parallel with the battery 310. The combination of transistors 412, 442 and 425, and resistors 410, 444, 446 and 448 acts as a constant current source generated at the collector of transistor 426. The transistor 412 has collector connected to the emitter of transistor 442 and base of transistor 425. The transistors 412 and 442 are connected to provide a constant voltage drop. Likewise, transistor 426 also acts as a diode with a resistor 428 connected in series and further connected to the negative terminal of the line at terminal 460. Capacitor 416 provides timing characteristics and its value helps determine pulse width and pulse frequency. The output of the oscillator appears at terminal 458.
Initially, the capacitor 416 gets charged with current from the path of resistor 434 and 436 while all the transistors are turned off. As the capacitor charges up transistor 432 will become forward biased and current will flow via resistors 430 and 436 from the base to emitter resistors. This action turns on the transistor 418 and the positive voltage from the power supply 310 is made available at the base of transistor 438 through resistor 440. This results in the transistor 438 getting turned on. The conduction of transistor 438 causes capacitor 416 to discharge. The time constant for the charge and discharge of capacitor 416 is determined by value of the resistors 428 and 440 and capacitor 416. After the time constant, transistor 432 turns off, and this in turn turns off transistors 438 and 418. A reset mechanism for this multivibrator can be provided by setting a positive voltage, for example 2.5 volts, to the base of transistor 420. This positive increase in voltage turns on transistor 420 followed by transistor 438. The turning on of transistor 438 discharges the capacitor 416 and the reset operation is complete.
Conventional microprocessor and integrated circuits are used for the logic, control and timing circuits. Conventional bipolar transistors are used in radio-frecuency oscillator, pulse amplitude ramp control and power amplifier. A standard voltage regulator is used in low-voltage detector. The hardware and software to deliver the pre-determined programs is well known to those skilled in the art.
The pulses delivered to the nerve tissue for stimulation therapy are shown graphically in FIG. 19. As shown in FIG. 20, for patient comfort when the electrical stimulation is turned on, the electrical stimulation is ramped up and ramped down, instead of abrupt delivery of electrical pulses.
The number of predetermined programs can be any number, say 100, and such a number is considered within the scope of the invention. For patient convenience, less than 20 programs are practical. One embodiment contains nine predetermined programs.
In one arrangement, the predetermined programs are arranged in such a way that the aggressiveness of the therapy increases from program #1 to Program #9. Thus the first three programs provide the least aggressive therapy, and the last three programs provide the most aggressive therapy.
The following are examples of least aggressive therapy.
1.0 mA current output, 0.2 msec pulse width, 15 Hz frequency, 15 sec on-time, 1.0 min off-time, in repeating cycles.
1.5 mA current output, 0.3 msec pulse width, 20 Hz frequency, 20 sec on-time, 2.0 min off-time, in repeating cycles.
The following are examples of intermediate level of therapy.
2.0 mA current output, 0.3 msec pulse width, 25 Hz frequency, 20 sec on-time, 1.0 min off-time, in repeating cycles.
2.0 mA current output, 0.4 msec pulse width, 25 Hz frequency, 30 sec on-time, 1.0 min off-time, in repeating cycles.
The following are examples of most aggressive therapy.
2.5 mA current output, 0.3 msec pulse width, 30 Hz frequency, 40 sec on-time, 1.5 min off-time, in repeating cycles.
3.0 mA current output, 0.5 msec pulse width, 30 Hz frequency, 30 sec on-time, 1.0 min off-time, in repeating cycles.
The majority of patients will fall into the category that require an intermediate level of therapy, such as program #5. The above are examples of the predetermined programs that are delivered to the vagus nerve. The actual parameter settings for any given patient may deviate somewhat from the above. As shown schematically in FIG. 13, new predetermined programs can be loaded into the external stimulator 42.
In one embodiment, the external stimulator can also have a telecommunications module, as described in a co-pending application, and summarized here for reader convenience. The telecommunications module has two-way communications capabilities.
FIG. 21 shows conceptually the communication between the external stimulator 42 and a remote hand-held computer. A desktop or laptop computer can be a server 500 which is situated remotely, perhaps at a physician's office or a hospital. The stimulation parameter data can be viewed at this facility or reviewed remotely by medical personnel on a hand-held personal data assistant (PDA) 502, such as a “palm-pilot” from PALM corp. (Santa Clara, Calif.), a “Visor” from Handspring Corp. (Mountain View, Calif.) or on a personal computer (PC) available from numerous vendors. The physician or appropriate medical personnel, is able to interrogate the external stimulator 42 device and know what the device is currently programmed to, as well as, get a graphical display of the pulse train. The wireless communication with the remote server 500 and hand-held PDA 502 would be supported in all geographical locations within and outside the United States (US) that provides cell phone voice and data communication service. The pulse generation parameter data can also be viewed on the handheld devices (PDA) 502.
The telecommunications component of this invention uses Wireless Application Protocol (WAP). The Wireless Application Protocol (WAP) is a set of communication protocols standardizing Internet access for wireless devices. While previously, manufacturers used different technologies to get Internet on hand-held devices, with WAP devices and services interoperate. WAP promotes convergence of wireless data and the Internet. The WAP programming model is heavily based on the existing Internet programming model, and is shown schematically in FIG. 22. Introducing a gateway function provides a mechanism for optimizing and extending this model to match the characteristics of the wireless environment. Over-the-air traffic is minimized by binary encoding/decoding of Web pages and readapting the Internet Protocol stack to accommodate the unique characteristics of a wireless medium such as call drops. Such features are facilitated with WAP.
The key components of the WAP technology, as shown in FIG. 22, includes 1) Wireless Mark-up Language (WML) 400 which incorporates the concept of cards and decks, where a card is a single unit of interaction with the user. A service constitutes a number of cards collected in a deck. A card can be displayed on a small screen. WML supported Web pages reside on traditional Web servers. 2) WML Script which is a scripting language, enables application modules or applets to be dynamically transmitted to the client device and allows the user interaction with these applets. 3) Microbrowser, which is a lightweight application resident on the wireless terminal that controls the user interface and interprets the WML/WMLScript content. 4) A lightweight protocol stack 402 which minimizes bandwidth requirements, guaranteeing that a broad range of wireless networks can run WAP applications. The protocol stack of WAP can comprise a set of protocols for the transport (WTP), session (WSP), and security (WTLS) layers. WSP is binary encoded and able to support header caching, thereby economizing on bandwidth requirements. WSP also compensates for high latency by allowing requests and responses to be handled asynchronously, sending before receiving the response to an earlier request. For lost data segments, perhaps due to fading or lack of coverage, WTP only retransmits lost segments using selective retransmission, thereby compensating for a less stable connection in wireless. The above mentioned features are industry standards adopted for wireless applications and greater details have been publicized, and well known to those skilled in the art.
In this embodiment, two modes of communication are possible. In the first, the server initiates an upload of the actual parameters being applied to the patient, receives these from the stimulator, and stores these in its memory, accessible to the authorized user as a dedicated content driven web page. The physician or authorized user can make alterations to the actual parameters, as available on the server, and then initiate a communication session with the stimulator device to download these parameters.
The physician is also able to set up long-term schedules of stimulation therapy for their patient population, through wireless communication with the server. The server in turn communicates these programs to the neurostimulator. Each schedule is securely maintained on the server, and is editable by the physician and can get uploaded to the patient's stimulator device at a scheduled time. Thus, therapy can be customized for each individual patient. Each device issued to a patient has a unique identification key in order to guarantee secure communication between the wireless server 502 and stimulator device 42.
The second mode of communication is the ability to remotely interrogate and monitor the stimulation therapy on the physician's handheld (PDA) 502.
Moving now to the implantable portion of the system, FIG. 23A shows a diagram of the implanted lead-receiver 34, and FIG. 23B shows a diagram of the proximal end 49 of the lead-receiver 34. The proximal end 49 is a relatively flat portion and contains the electrical components on a printed circuit board. The distal end has the two spiral electrodes 61 and 62 for stimulating the nerve. The passive circuitry and electrodes are connected by electrically insulated wire conductors running within the lead body 59. The lead body 59 is made of reinforced medical grade silicone in the presently preferred embodiment.
The circuitry contained in the proximal end 49 of the implantable lead-receiver 34 is shown schematically in FIG. 24, for the presently preffered embodiment. In this embodiment, the circuit uses all passive components. Approximately 25 turn copper wire of 30 gauge, or comparable thickness, is used for the primary coil 46 and secondary coil 48. This wire is concentrically wound with the windings all in one plane. The frequency of the pulse-waveform delivered to the implanted coil 48 can vary and so a variable capacitor 152 provides ability to tune secondary implanted circuit 167 to the signal from the primary coil 46. The pulse signal from secondary (implanted) coil 48 is rectified by the diode bridge 154 and frequency reduction obtained by capacitor 158 and resistor 164. The last component in line is capacitor 166, used for isolating the output signal from the electrode wire. The return path of signal from cathode 61 will be through anode 62 placed in proximity to the cathode 61 for “Bipolar” stimulation. In the current embodiment bipolar mode of stimulation is used, however, the return path can be connected to the remote ground connection (case) of implantable circuit 167, providing for much larger intermediate tissue for “Unipolar” stimulation. The “Bipolar” stimulation offers localized stimulation of tissue compared to “Unipolar” stimulation and is therefore, used in the current embodiment. Unipolar stimulation is more likely to stimulate skeletal muscle in addition to nerve stimulation. The implanted circuit 167 in this embodiment is passive, so a battery does not have to be implanted. It is however possible to implant a battery source for use of active component logic in the implant.
The circuitry shown in FIGS. 25A and 25B can be used as an alternative, for the implanted lead-receiver. The circuitry of FIG. 25A is a slightly simpler version, and circuitry of FIG. 25B contains a conventional NPN transistor 168 connected in an emitter-follower configuration.
The fabrication of the lead-receiver 34 is designed to be modular. Thus, several different combinations of the components can be packaged without significantly altering the functionality of the device. As shown in FIG. 23A, the lead-receiver 34 components are the proximal end 49 containing coil 48, electrical circuitry 167, and case 78. The lead body 59 containing the conductor 65,66 and the distal end has two electrodes cathode 61 and anode 62. In the modular design concept, several design variables are possible, as shown in the table below.
Table of lead-receiver design variables
Either silicone or polyurethane is a suitable material for the implantable lead-receiver body 59. Both materials have proven to have desirable qualities which are not available in the other. Permanently implantable pacemaker leads made of polyurethane are susceptible to some forms of degradation over time. The identified mechanisms are Environmental Stress Cracking (ESC) and Metal Ion Oxidation (MIO). Silicone on the other hand is a softer material, therefore lead body has to be made bigger. In the presently preferred embodiment silicone re-enforced with polytetrafluroethyene (PTFE) is used.
Nerve-electrode interaction is an integral part of the stimulation system. As a practical benefit of modular design, any type of electrode described below can be used as the distal (cathode) stimulating electrode, without changing fabrication methodology or procedure significantly. When a standard electrode made of platinum or platinum/iridium is placed next to the nerve, and secured in place, it promotes an inflammatory response that leads to a thin fibrotic sheath around the electrode over a period of 1 to 6 weeks. This in turn leads to a stable position of electrode relative to the nerve, and a stable electrode-tissue interface, resulting in reliable stimulation of the nerve chronically without damaging the nerve.
Alternatively, other electrode forms that are non-traumatic to the nerve such as hydrogel, platinum fiber, or steroid elution electrodes may be used with this system. The concept of hydrogel electrode for nerve stimulation is shown schematically in FIG. 26. The hydrogel material 100 is wrapped around the nerve 54, with tiny platinum electrodes 102 being pulled back from nerve. Over a period of time in the body, the hydrogel material 100 will undergo degradation and there will be fibrotic tissue buildup. Because of the softness of the hydrogel material 100, these electrodes are non-traumatic to the nerve.
The concept of platinum fiber electrodes is shown schematically in FIG. 27. The distal fiber electrode 104 attached to the lead-receiver 34 may be platinum fiber or cable, or the electrode may be thin platinum fiber wrapped around Dacron polyester or Polyimide 106. As shown in FIG. 28, the platinum fibers 108 may be woven around Dacron polyester fiber 106 or platinum fibers 108 may be braided. At implant, the fiber electrode 104 is loosely wrapped around the surgically isolated nerve, then tied loosely so as not to constrict the nerve or put pressure on the nerve. As a further extension, the fiber electrode may be incorporated into a spiral electrode 105 as is shown schematically in FIG. 29. The two “pigs tail” coil electrodes are made from thin platinum coated braided yarn which is adhered to a substrate in the shape of a “pigs tail” and wraps around the nerve. The braid then continues up a silicone tube lead body.
Alternatively, steroid elution electrodes may be used. After implantation of a lead in the body, during the first few weeks there is buildup of fibrotic tissue in-growth over the electrode and to some extent around the lead body. This fibrosis is the end result of body's inflammatory response process which begins soon after the device is implanted. The fibrotic tissue sheath has the net effect of increasing the distance between the stimulation electrode (cathode) and the excitable tissue, which is the vagal nerve in this case. This is shown schematically in FIG. 30, where electrode 52 when covered with fibrotic tissue becomes the “virtual” electrode 114. Non-excitable tissue is depicted as 120 and excitable tissue as 118. A small amount of corticosteroid, dexamethasone sodium phosphate, which is commonly referred to as “steroid” or “dexamethasone” placed inside or around the electrode, has significant beneficial effect on the current or energy threshold, i.e. the amount of energy required to stimulate the excitable tissue. This is well known to those familiar in the art, as there is a long history of steroid elution leads in cardiac pacing application. It takes only about 1 mg of dexamethasone to produce the desirable effects. Three separate ways of delivering the steroid drug to the electrode nerve-tissue interface are being disclosed here. Dexamethasone can be placed inside an electrode with microholes, it can be placed adjacent to the electrode in a silicone collar, or it can be coated on the electrode itself.
Dexamethasone inside the stimulating electrode is shown schematically in FIG. 31. A silicone core that is impregnated with a small quantity of dexamethasone 121, is incorporated inside the electrode. The electrode tip is depicted as 124 and electrode body as 122. Once the lead is implanted in the body, the steroid 121 elutes out through the small holes in the electrode. The steroid drug then has anti-inflammatory action at the electrode tissue interface, which leads to a much thinner fibrotic tissue capsule.
Another way of having a steroid eluting nerve stimulating electrode, is to have the steroid agent placed outside the distal electrode 91 in a silicone collar 126. This is shown schematically in FIG. 32. Approximately 1 mg of dexamethasone is contained in a silicone collar 126, at the base of the distal electrode 52. With such a method, the steroid drug elutes around the electrode 52 in a similar fashion and with similar pharmacokinetic properties, as with the steroid drug being inside the electrode.
Another method of steroid elution for nerve stimulation electrodes is by coating of steroid on the outside (exposed) surface area of the electrode. This is shown schematically in FIG. 33. Nafion is used as the coating matrix. Steroid membrane coating on the outside of the electrode is depicted as 128. The advantages of this method are that it can easily be applied to any electrode, fast and easy manufacturing, and it is cost effective. With this method, the rate of steroid delivery can be controlled by the level of sulfonation.
A schematic representation of the cross section of different possible lumens is shown in FIG. 34. The lead body 59 can have one, two, or three lumens for conducting cable, with or without a hollow lumen. In the cross sections, 132A-F represents lumens(s) for conducting cable, and 134A-C represents hollow lumen for an aid in implanting the lead.
Additionally, different classes of coating may be applied to the implantable lead-receiver 34 after fabrication. These coatings fall into three categories, lubricious coating, antimicrobial coating, and anti-inflammatory coating.
The advantage of modular fabrication is that with one technology platform, several derivative products or models can be manufactured. As a specific practical example, using a silicone lead body platform, three separate derivative or lead models can be manufactured by using three different electrodes such as standard ball electrode, spiral electrode, or steroid electrode. This is made possible by designing the fabrication steps such that the distal electrodes are assembled at the end, and as long as the electrodes are mated to the insulation and conducting cable, the shape or type of electrode does not matter. Similarly, different models can be produced by taking a finished lead and then coating it with lubricious coating or antimicrobial coating. In fact, considering the design variables disclosed in Table 1, a large number of combinations are possible.
While various embodiments of the present invention have been described in detail, it is apparent that modifications and adaptations of those embodiments will occur to those skilled in the art. However, it is to be expressly understood that such modifications and adaptations are within the spirit and scope of the present invention.
|Patente citada||Fecha de presentación||Fecha de publicación||Solicitante||Título|
|US3760812||19 Mar 1971||25 Sep 1973||Univ Minnesota||Implantable spiral wound stimulation electrodes|
|US3796221||7 Jul 1971||12 Mar 1974||Hagfors N||Apparatus for delivering electrical stimulation energy to body-implanted apparatus with signal-receiving means|
|US4573481 *||25 Jun 1984||4 Mar 1986||Huntington Institute Of Applied Research||Implantable electrode array|
|US4702254||30 Dic 1985||27 Oct 1987||Jacob Zabara||Neurocybernetic prosthesis|
|US4867164||26 Oct 1987||19 Sep 1989||Jacob Zabara||Neurocybernetic prosthesis|
|US4979511||3 Nov 1989||25 Dic 1990||Cyberonics, Inc.||Strain relief tether for implantable electrode|
|US5025807||25 Ene 1989||25 Jun 1991||Jacob Zabara||Neurocybernetic prosthesis|
|US5231988 *||9 Ago 1991||3 Ago 1993||Cyberonics, Inc.||Treatment of endocrine disorders by nerve stimulation|
|US5304206||18 Nov 1991||19 Abr 1994||Cyberonics, Inc.||Activation techniques for implantable medical device|
|US5571150 *||19 Dic 1994||5 Nov 1996||Cyberonics, Inc.||Treatment of patients in coma by nerve stimulation|
|US5611350 *||8 Feb 1996||18 Mar 1997||John; Michael S.||Method and apparatus for facilitating recovery of patients in deep coma|
|US5690693 *||7 Jun 1995||25 Nov 1997||Sulzer Intermedics Inc.||Transcutaneous energy transmission circuit for implantable medical device|
|US5755766 *||24 Ene 1997||26 May 1998||Cardiac Pacemakers, Inc.||Open-ended intravenous cardiac lead|
|US6205359 *||26 Oct 1998||20 Mar 2001||Birinder Bob Boveja||Apparatus and method for adjunct (add-on) therapy of partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator|
|Patente citante||Fecha de presentación||Fecha de publicación||Solicitante||Título|
|US7206632 *||30 Ene 2004||17 Abr 2007||Medtronic, Inc.||Patient sensory response evaluation for neuromodulation efficacy rating|
|US7299091||1 Jul 2003||20 Nov 2007||Cyberonics, Inc.||Treatment of obesity by bilateral vagus nerve stimulation|
|US7310557||29 Abr 2005||18 Dic 2007||Maschino Steven E||Identification of electrodes for nerve stimulation in the treatment of eating disorders|
|US7340306||18 Ago 2003||4 Mar 2008||Cyberonics, Inc.||Treatment of obesity by sub-diaphragmatic nerve stimulation|
|US7657310||26 Ene 2006||2 Feb 2010||Cyberonics, Inc.||Treatment of reproductive endocrine disorders by vagus nerve stimulation|
|US7676275||2 May 2005||9 Mar 2010||Pacesetter, Inc.||Endovascular lead for chronic nerve stimulation|
|US7705016||12 Feb 2004||27 Abr 2010||Albert Einstein College Of Medicine Of Yeshiva University||Regulation of food intake by modulation of long-chain fatty acyl-CoA levels in the hypothalamus|
|US7706874||28 Jul 2005||27 Abr 2010||Cyberonics, Inc.||Stimulating cranial nerve to treat disorders associated with the thyroid gland|
|US7706875||25 Ene 2007||27 Abr 2010||Cyberonics, Inc.||Modulation of drug effects by vagus nerve stimulation|
|US7711419||13 Jul 2005||4 May 2010||Cyberonics, Inc.||Neurostimulator with reduced size|
|US7801601||27 Ene 2006||21 Sep 2010||Cyberonics, Inc.||Controlling neuromodulation using stimulus modalities|
|US7813805||11 Ene 2006||12 Oct 2010||Pacesetter, Inc.||Subcardiac threshold vagal nerve stimulation|
|US7835796||29 Abr 2005||16 Nov 2010||Cyberonics, Inc.||Weight loss method and device|
|US7856273||28 Jul 2005||21 Dic 2010||Cyberonics, Inc.||Autonomic nerve stimulation to treat a gastrointestinal disorder|
|US7869867||27 Oct 2006||11 Ene 2011||Cyberonics, Inc.||Implantable neurostimulator with refractory stimulation|
|US7869869||11 Ene 2006||11 Ene 2011||Pacesetter, Inc.||Subcardiac threshold vagal nerve stimulation|
|US7869884||26 Abr 2007||11 Ene 2011||Cyberonics, Inc.||Non-surgical device and methods for trans-esophageal vagus nerve stimulation|
|US7869885||28 Abr 2006||11 Ene 2011||Cyberonics, Inc||Threshold optimization for tissue stimulation therapy|
|US7894907||18 Jun 2007||22 Feb 2011||Ebr Systems, Inc.||Systems and methods for implantable leadless nerve stimulation|
|US7899540||29 Abr 2005||1 Mar 2011||Cyberonics, Inc.||Noninvasively adjustable gastric band|
|US7904175||26 Abr 2007||8 Mar 2011||Cyberonics, Inc.||Trans-esophageal vagus nerve stimulation|
|US7962214||27 Jul 2007||14 Jun 2011||Cyberonics, Inc.||Non-surgical device and methods for trans-esophageal vagus nerve stimulation|
|US7962220||28 Abr 2006||14 Jun 2011||Cyberonics, Inc.||Compensation reduction in tissue stimulation therapy|
|US7974697||26 Ene 2006||5 Jul 2011||Cyberonics, Inc.||Medical imaging feedback for an implantable medical device|
|US7974701||27 Abr 2007||5 Jul 2011||Cyberonics, Inc.||Dosing limitation for an implantable medical device|
|US7996079||24 Ene 2006||9 Ago 2011||Cyberonics, Inc.||Input response override for an implantable medical device|
|US8068918||9 Mar 2007||29 Nov 2011||Enteromedics Inc.||Remote monitoring and control of implantable devices|
|US8140167||20 Nov 2007||20 Mar 2012||Enteromedics, Inc.||Implantable therapy system with external component having multiple operating modes|
|US8150508||29 Mar 2007||3 Abr 2012||Catholic Healthcare West||Vagus nerve stimulation method|
|US8204603||25 Abr 2008||19 Jun 2012||Cyberonics, Inc.||Blocking exogenous action potentials by an implantable medical device|
|US8219188||29 Mar 2007||10 Jul 2012||Catholic Healthcare West||Synchronization of vagus nerve stimulation with the cardiac cycle of a patient|
|US8224438||6 Ene 2010||17 Jul 2012||Levin Bruce H||Method for directed intranasal administration of a composition|
|US8239028||24 Abr 2009||7 Ago 2012||Cyberonics, Inc.||Use of cardiac parameters in methods and systems for treating a chronic medical condition|
|US8260426||25 Ene 2008||4 Sep 2012||Cyberonics, Inc.||Method, apparatus and system for bipolar charge utilization during stimulation by an implantable medical device|
|US8280505||10 Mar 2009||2 Oct 2012||Catholic Healthcare West||Vagus nerve stimulation method|
|US8306627||23 May 2011||6 Nov 2012||Cyberonics, Inc.||Dosing limitation for an implantable medical device|
|US8326426||3 Abr 2009||4 Dic 2012||Enteromedics, Inc.||Implantable device with heat storage|
|US8337404||1 Oct 2010||25 Dic 2012||Flint Hills Scientific, Llc||Detecting, quantifying, and/or classifying seizures using multimodal data|
|US8382667||29 Abr 2011||26 Feb 2013||Flint Hills Scientific, Llc||Detecting, quantifying, and/or classifying seizures using multimodal data|
|US8391970||26 Ago 2008||5 Mar 2013||The Feinstein Institute For Medical Research||Devices and methods for inhibiting granulocyte activation by neural stimulation|
|US8412336||29 Dic 2009||2 Abr 2013||Autonomic Technologies, Inc.||Integrated delivery and visualization tool for a neuromodulation system|
|US8412338||17 Nov 2009||2 Abr 2013||Setpoint Medical Corporation||Devices and methods for optimizing electrode placement for anti-inflamatory stimulation|
|US8417344||24 Oct 2008||9 Abr 2013||Cyberonics, Inc.||Dynamic cranial nerve stimulation based on brain state determination from cardiac data|
|US8428731||27 Oct 2005||23 Abr 2013||Cyberonics, Inc.||Sequenced therapy protocols for an implantable medical device|
|US8452387||20 Sep 2010||28 May 2013||Flint Hills Scientific, Llc||Detecting or validating a detection of a state change from a template of heart rate derivative shape or heart beat wave complex|
|US8457747||20 Oct 2008||4 Jun 2013||Cyberonics, Inc.||Neurostimulation with signal duration determined by a cardiac cycle|
|US8473062||1 May 2009||25 Jun 2013||Autonomic Technologies, Inc.||Method and device for the treatment of headache|
|US8494641||22 Abr 2010||23 Jul 2013||Autonomic Technologies, Inc.||Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism|
|US8494643||18 Ene 2011||23 Jul 2013||Ebr Systems, Inc.||Systems and methods for implantable leadless nerve stimulation|
|US8521299||9 Nov 2011||27 Ago 2013||Enteromedics Inc.||Remote monitoring and control of implantable devices|
|US8532787||20 Nov 2007||10 Sep 2013||Enteromedics Inc.||Implantable therapy system having multiple operating modes|
|US8538533||19 Oct 2011||17 Sep 2013||Enteromedics Inc.||Controlled vagal blockage therapy|
|US8538542||21 Jul 2011||17 Sep 2013||Enteromedics Inc.||Nerve stimulation and blocking for treatment of gastrointestinal disorders|
|US8562536||29 Abr 2010||22 Oct 2013||Flint Hills Scientific, Llc||Algorithm for detecting a seizure from cardiac data|
|US8565867||25 Ene 2008||22 Oct 2013||Cyberonics, Inc.||Changeable electrode polarity stimulation by an implantable medical device|
|US8571643||16 Sep 2010||29 Oct 2013||Flint Hills Scientific, Llc||Detecting or validating a detection of a state change from a template of heart rate derivative shape or heart beat wave complex|
|US8594806||30 Abr 2010||26 Nov 2013||Cyberonics, Inc.||Recharging and communication lead for an implantable device|
|US8612002||23 Dic 2010||17 Dic 2013||Setpoint Medical Corporation||Neural stimulation devices and systems for treatment of chronic inflammation|
|US8615309||29 Mar 2007||24 Dic 2013||Catholic Healthcare West||Microburst electrical stimulation of cranial nerves for the treatment of medical conditions|
|US8634930||30 Jun 2006||21 Ene 2014||Cardiac Pacemakers, Inc.||System for providing diabetic therapy|
|US8641646||30 Jul 2010||4 Feb 2014||Cyberonics, Inc.||Seizure detection using coordinate data|
|US8649871||30 Abr 2010||11 Feb 2014||Cyberonics, Inc.||Validity test adaptive constraint modification for cardiac data used for detection of state changes|
|US8660647||28 Jul 2005||25 Feb 2014||Cyberonics, Inc.||Stimulating cranial nerve to treat pulmonary disorder|
|US8660666||10 Mar 2009||25 Feb 2014||Catholic Healthcare West||Microburst electrical stimulation of cranial nerves for the treatment of medical conditions|
|US8679009||15 Jun 2010||25 Mar 2014||Flint Hills Scientific, Llc||Systems approach to comorbidity assessment|
|US8684921||15 May 2012||1 Abr 2014||Flint Hills Scientific Llc||Detecting, assessing and managing epilepsy using a multi-variate, metric-based classification analysis|
|US8694118||28 Oct 2005||8 Abr 2014||Cyberonics, Inc.||Variable output ramping for an implantable medical device|
|US8725239||25 Abr 2011||13 May 2014||Cyberonics, Inc.||Identifying seizures using heart rate decrease|
|US8729129||24 Mar 2005||20 May 2014||The Feinstein Institute For Medical Research||Neural tourniquet|
|US8738126||10 Mar 2009||27 May 2014||Catholic Healthcare West||Synchronization of vagus nerve stimulation with the cardiac cycle of a patient|
|US8768471||3 Mar 2013||1 Jul 2014||Cyberonics, Inc.||Dynamic cranial nerve stimulation based on brain state determination from cardiac data|
|US8781574||4 Mar 2013||15 Jul 2014||Autonomic Technologies, Inc.||Integrated delivery and visualization tool for a neuromodulation system|
|US8788034||9 May 2012||22 Jul 2014||Setpoint Medical Corporation||Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation|
|US8827912||27 Abr 2010||9 Sep 2014||Cyberonics, Inc.||Methods and systems for detecting epileptic events using NNXX, optionally with nonlinear analysis parameters|
|US8831732||30 Abr 2010||9 Sep 2014||Cyberonics, Inc.||Method, apparatus and system for validating and quantifying cardiac beat data quality|
|US8849409||3 Mar 2013||30 Sep 2014||Cyberonics, Inc.||Dynamic cranial nerve stimulation based on brain state determination from cardiac data|
|US8849412||13 Ago 2012||30 Sep 2014||Micron Devices Llc||Microwave field stimulator|
|US8852100||25 Feb 2013||7 Oct 2014||Flint Hills Scientific, Llc||Detecting, quantifying, and/or classifying seizures using multimodal data|
|US8855767||15 Nov 2013||7 Oct 2014||Setpoint Medical Corporation||Neural stimulation devices and systems for treatment of chronic inflammation|
|US8874218||23 Abr 2013||28 Oct 2014||Cyberonics, Inc.||Neurostimulation with signal duration determined by a cardiac cycle|
|US8886325||10 Jul 2013||11 Nov 2014||Autonomic Technologies, Inc.||Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism|
|US8886339||9 Jun 2010||11 Nov 2014||Setpoint Medical Corporation||Nerve cuff with pocket for leadless stimulator|
|US8888702||3 Dic 2012||18 Nov 2014||Flint Hills Scientific, Llc||Detecting, quantifying, and/or classifying seizures using multimodal data|
|US8903502||19 May 2013||2 Dic 2014||Micron Devices Llc||Methods and devices for modulating excitable tissue of the exiting spinal nerves|
|US8914114||17 Nov 2004||16 Dic 2014||The Feinstein Institute For Medical Research||Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation|
|US8945006||24 Feb 2014||3 Feb 2015||Flunt Hills Scientific, LLC||Detecting, assessing and managing epilepsy using a multi-variate, metric-based classification analysis|
|US8948855||21 May 2013||3 Feb 2015||Flint Hills Scientific, Llc||Detecting and validating a detection of a state change from a template of heart rate derivative shape or heart beat wave complex|
|US8996116||1 Nov 2010||31 Mar 2015||Setpoint Medical Corporation||Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction|
|US9020582||30 Sep 2013||28 Abr 2015||Flint Hills Scientific, Llc||Detecting or validating a detection of a state change from a template of heart rate derivative shape or heart beat wave complex|
|US9050469||24 Nov 2004||9 Jun 2015||Flint Hills Scientific, Llc||Method and system for logging quantitative seizure information and assessing efficacy of therapy using cardiac signals|
|US9056195||15 Mar 2013||16 Jun 2015||Cyberonics, Inc.||Optimization of cranial nerve stimulation to treat seizure disorderse during sleep|
|US9108041||25 Nov 2013||18 Ago 2015||Dignity Health||Microburst electrical stimulation of cranial nerves for the treatment of medical conditions|
|US9162062||16 Sep 2013||20 Oct 2015||Enteromedics Inc.||Controlled vagal blockage therapy|
|US9162064||7 Oct 2014||20 Oct 2015||Setpoint Medical Corporation||Neural stimulation devices and systems for treatment of chronic inflammation|
|US9171343||14 Sep 2012||27 Oct 2015||Aseko, Inc.||Means and method for improved glycemic control for diabetic patients|
|US9174040||5 Sep 2013||3 Nov 2015||Enteromedics Inc.||Nerve stimulation and blocking for treatment of gastrointestinal disorders|
|US9174041||7 Nov 2014||3 Nov 2015||Setpoint Medical Corporation||Nerve cuff with pocket for leadless stimulator|
|US9199089||30 Jul 2012||1 Dic 2015||Micron Devices Llc||Remote control of power or polarity selection for a neural stimulator|
|US9211409||31 Mar 2009||15 Dic 2015||The Feinstein Institute For Medical Research||Methods and systems for reducing inflammation by neuromodulation of T-cell activity|
|US9211410||21 Jul 2014||15 Dic 2015||Setpoint Medical Corporation||Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation|
|US9220897||3 Oct 2013||29 Dic 2015||Micron Devices Llc||Implantable lead|
|US9220910||7 Ene 2014||29 Dic 2015||Cyberonics, Inc.||Seizure detection using coordinate data|
|US9233204||27 Oct 2014||12 Ene 2016||Aseko, Inc.||Insulin management|
|US9241647||21 Oct 2013||26 Ene 2016||Cyberonics, Inc.||Algorithm for detecting a seizure from cardiac data|
|US9242103||17 Sep 2012||26 Ene 2016||Micron Devices Llc||Relay module for implant|
|US9289599||3 Abr 2012||22 Mar 2016||Dignity Health||Vagus nerve stimulation method|
|US9302096||24 Mar 2015||5 Abr 2016||Bruce H. Levin||Apparatus for treating cerebral neurovascular disorders including headaches by neural stimulation|
|US9302109||25 Abr 2014||5 Abr 2016||Cyberonics, Inc.||Cranial nerve stimulation to treat depression during sleep|
|US9314633||31 Ago 2012||19 Abr 2016||Cyberonics, Inc.||Contingent cardio-protection for epilepsy patients|
|US9320908||15 Ene 2010||26 Abr 2016||Autonomic Technologies, Inc.||Approval per use implanted neurostimulator|
|US9343923||23 Ago 2012||17 May 2016||Cyberonics, Inc.||Implantable medical device with backscatter signal based communication|
|US9381349||6 Jun 2014||5 Jul 2016||Bhl Patent Holdings Llc||Apparatus for treating cerebral neurovascular disorders including headaches by neural stimulation|
|US9402550||29 Abr 2011||2 Ago 2016||Cybertronics, Inc.||Dynamic heart rate threshold for neurological event detection|
|US9409029||12 May 2015||9 Ago 2016||Micron Devices Llc||Remote RF power system with low profile transmitting antenna|
|US9409030||17 Jul 2012||9 Ago 2016||Micron Devices Llc||Neural stimulator system|
|US9435830||18 Ene 2013||6 Sep 2016||Cyberonics, Inc.||Implantable medical device depth estimation|
|US9452286||20 Jun 2013||27 Sep 2016||Ebr Systems, Inc.||Systems and methods for implantable leadless tissue stimulation|
|US9483619||22 Sep 2015||1 Nov 2016||Aseko, Inc.||Means and method for improved glycemic control for diabetic patients|
|US9486580||9 Oct 2014||8 Nov 2016||Aseko, Inc.||Insulin management|
|US9498162||25 Abr 2011||22 Nov 2016||Cyberonics, Inc.||Identifying seizures using heart data from two or more windows|
|US9504390||13 Sep 2013||29 Nov 2016||Globalfoundries Inc.||Detecting, assessing and managing a risk of death in epilepsy|
|US9504789||12 Nov 2015||29 Nov 2016||Aseko, Inc.||Insulin management|
|US9533151||10 Ene 2014||3 Ene 2017||Dignity Health||Microburst electrical stimulation of cranial nerves for the treatment of medical conditions|
|US9554694||23 Jun 2014||31 Ene 2017||Autonomic Technologies, Inc.||Integrated delivery and visualization tool for a neuromodulation system|
|US9566449||31 Oct 2013||14 Feb 2017||Micro Devices, LLC||Neural stimulator system|
|US9572983||26 Mar 2013||21 Feb 2017||Setpoint Medical Corporation||Devices and methods for modulation of bone erosion|
|US9585611||25 Abr 2014||7 Mar 2017||Cyberonics, Inc.||Detecting seizures based on heartbeat data|
|US9586047||21 Nov 2015||7 Mar 2017||Cyberonics, Inc.||Contingent cardio-protection for epilepsy patients|
|US9604002||22 Sep 2016||28 Mar 2017||Aseko, Inc.||Insulin management|
|US9616234||10 Abr 2014||11 Abr 2017||Trustees Of Boston University||System and method for neuro-stimulation|
|US9662490||11 Dic 2015||30 May 2017||The Feinstein Institute For Medical Research||Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug|
|US9682233||2 Nov 2015||20 Jun 2017||Enteromedics Inc.||Nerve stimulation and blocking for treatment of gastrointestinal disorders|
|US9700256||7 Dic 2015||11 Jul 2017||Cyberonics, Inc.||Algorithm for detecting a seizure from cardiac data|
|US9700716||3 Nov 2015||11 Jul 2017||Setpoint Medical Corporation||Nerve cuff with pocket for leadless stimulator|
|US9700723||13 May 2015||11 Jul 2017||Cyberonics, Inc.||Optimization of cranial nerve stimulation to treat seizure disorders during sleep|
|US20050075669 *||30 Ene 2004||7 Abr 2005||King Gary W.||Patient sensory response evaluation for neuromodulation efficacy rating|
|US20050250999 *||10 Dic 2004||10 Nov 2005||Ok-Kyung Cho||Blood sugar level measuring apparatus|
|US20050251220 *||15 Sep 2003||10 Nov 2005||Barrett Burke T||Treatment of neuropsychiatric disorders by near-diaphragmatic nerve stimulation|
|US20050261561 *||20 May 2005||24 Nov 2005||Christopher W. Jones||Blood testing and therapeutic compound delivery system|
|US20060063990 *||22 Nov 2004||23 Mar 2006||Ok-Kyung Cho||Blood sugar level measuring apparatus|
|US20060247719 *||29 Abr 2005||2 Nov 2006||Cyberonics, Inc.||Weight loss method and advice|
|US20060247721 *||29 Abr 2005||2 Nov 2006||Cyberonics, Inc.||Identification of electrodes for nerve stimulation in the treatment of eating disorders|
|US20060247722 *||29 Abr 2005||2 Nov 2006||Cyberonics, Inc.||Noninvasively adjustable gastric band|
|US20070016263 *||13 Jul 2005||18 Ene 2007||Cyberonics, Inc.||Neurostimulator with reduced size|
|US20070027496 *||28 Jul 2005||1 Feb 2007||Cyberonics, Inc.||Stimulating cranial nerve to treat pulmonary disorder|
|US20070097593 *||28 Oct 2005||3 May 2007||Cyberonics, Inc.||Variable output ramping for an implantable medical device|
|US20070100377 *||28 Oct 2005||3 May 2007||Cyberonics, Inc.||Providing multiple signal modes for a medical device|
|US20070100391 *||27 Oct 2005||3 May 2007||Cyberonics, Inc.||Sequenced therapy protocols for an implantable medical device|
|US20070112327 *||1 Nov 2006||17 May 2007||Yun Anthony J||Methods and compositions for treating a renal disease condition in a subject|
|US20070173902 *||26 Ene 2006||26 Jul 2007||Cyberonics, Inc.||Medical imaging feedback for an implantable medical device|
|US20070203548 *||22 Mar 2005||30 Ago 2007||Pawelzik Klaus R||System And Device Implantable In Tissue Of A Living Being For Recording And Influencing Electrical Bio-Activity|
|US20070293906 *||18 Jun 2007||20 Dic 2007||Ebr Systems, Inc.||Systems and methods for implantable leadless nerve stimulation|
|US20080004672 *||30 Jun 2006||3 Ene 2008||Yousufali Dalal||System for providing diabetic therapy|
|US20080015642 *||17 Jul 2006||17 Ene 2008||Sherwood Services Ag||Method for stimulation of the vagus nerve|
|US20080077192 *||29 Oct 2007||27 Mar 2008||Afferent Corporation||System and method for neuro-stimulation|
|US20080183226 *||25 Ene 2007||31 Jul 2008||Cyberonics, Inc.||Modulation of drug effects by vagus nerve stimulation|
|US20090254133 *||7 Abr 2008||8 Oct 2009||Wendell Keith F||Method for treatment of diabetes by electrostimulatioin|
|US20100057158 *||26 Ago 2008||4 Mar 2010||Pacesetter, Inc.||Neurostimulation Based On Glycemic Condition|
|US20100256708 *||3 Abr 2009||7 Oct 2010||Thornton Arnold W||Implantable device with heat storage|
|US20110118810 *||18 Ene 2011||19 May 2011||Ebr Systems, Inc.||Systems and methods for implantable leadless nerve stimulation|
|WO2005094669A1 *||22 Mar 2005||13 Oct 2005||Universität Bremen||System and device implantable in tissue of a living being for recording and influencing electrical bio-activity|
|Clasificación de EE.UU.||607/2|
|Clasificación cooperativa||A61N1/36017, A61N1/0536, A61N1/37282, A61N1/37223, A61N1/36007, A61N1/36053|
|Clasificación europea||A61N1/36Z, A61N1/36E, A61N1/36|
|14 Dic 2006||FPAY||Fee payment|
Year of fee payment: 4
|11 Abr 2011||REMI||Maintenance fee reminder mailed|
|2 Sep 2011||LAPS||Lapse for failure to pay maintenance fees|
|25 Oct 2011||FP||Expired due to failure to pay maintenance fee|
Effective date: 20110902